NYMX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 liep. 2023 @ 23:00):

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally...

Stats
Dzisiejszy wolumen	881 574
Średni wolumen	134 777
Kapitalizacja rynkowa	18.24M
EPS	$0.0100 ( 2023-08-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.161 (16.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2022-05-02	Robinson James George	Buy	1 151 515	Warrant
2021-04-22	Robinson James George	Buy	200	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 546 252 \| Sell: 0

Wolumen Korelacja

Długi: -0.08 (neutral)

Krótki: -0.02 (neutral)

Signal:(67.127) Neutral

Nymox Pharmaceutical Corp Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nymox Pharmaceutical Corp Korelacja - Waluta/Towar

-0.25
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

-0.04
( neutral )

0.38
( neutral )

Nymox Pharmaceutical Corp Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.0735

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.0735

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.150

FY	2020
Przychody:	$5 000.00
Zysk brutto:	$1 000.00 (20.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.